Sign in
CompletedNo phase

The Efficacy and Safety of Corticosteroids in Combination With Ruxolitinib in the Management of Checkpoint Inhibitor Pneumonia

Key facts

Who runs it
Peking Union Medical College Hospital
Where
China4 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
60 people enrolled
Started
14 Apr 2023
Ended
30 Jun 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Corticosteroids
  • Corticosteroids and Ruxolitinib
Record updated
28 July 2026

Who can take part

Age
15 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • 18 years old≤ Aged ≤80 years old
  • Diagnosis of malignancy
  • Malignant tumors initially treated with immune checkpoint inhibitors (antibodies targeting PD-1, PD-L1, CTLA-4, or new immune checkpoint inhibitors) in combination with or without chemotherapy
  • Diagnosis of grade 3 or 4 CIP: CIP severity at CTCAE grade 3 or 4
  • Patients who and whose family members understand the study protocol, are willing to participate in the study and could provide written informed consent

Who cannot take part

  • Any evidence of active or uncontrolled viral infection, including hepatitis B, hepatitis C and human immunodeficiency virus (HIV), or any clinical signs of bacterial, other viral, parasitic or fungal infection requiring treatment
  • malignancy progression
  • Any significant clinical and laboratory abnormalities judged by investigator that affect the safety evaluation
  • Predicted life expectancy<12 weeks
  • Patients with other serious complications that may affect safety or adherence judged by the investigator
  • Patients can't fully understand the study protocol, arrangement and other study-related elements
  • Patients with evidence of severe liver or kidney dysfunction judged by investigator unsuitable for enrolment
  • Women who are pregnant, breast feeding or unable to use effective contraception during the study period and for 3 months after the completion
  • Patients who cannot comply with study treatment and follow-up according to the trial protocol

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study is a prospective multicenter randomized controlled Interventional study, to assess the clinical efficacy and safety of corticosteroids compared to corticosteroids in combination with Ruxolitinib in the treatment of severe checkpoint inhibitor pneumonitis.

The 2 groups in the trial

  • Cohort 1: severe CIP with the treatment of corticosteroidsExisting treatment, for comparison

    severe CIP with the treatment of corticosteroids

    Treatment: Corticosteroids

  • Cohort 2: severe CIP with the treatment of corticosteroids and RuxolitinibTreatment being tested

    severe CIP with the treatment of corticosteroids and Ruxolitinib

    Treatment: Corticosteroids and Ruxolitinib

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Efficacy and Safety of Corticosteroids in Combination With Biological Agents in the Management of Severe Immune Related Adverse Events Cohort A: The Efficacy and Safety of Corticosteroids or Corticosteroids Combination With Ruxolitinib in Patients With Severe Checkpoint Inhibitor Pneumonia
Record updated
28 July 2026